222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000384-23-DE
(EUCTR)
19/12/202217/05/2022A study to test BI 764198 in people with a type of kidney disease calledfocal segmental glomerulosclerosis.A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis - PoCP study in FSGS Focal segmental glomerulosclerosis
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Boehringer Ingelheim Pharma GmbH & Co. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2France;United States;Hungary;Belgium;Spain;Ireland;Australia;Germany;United Kingdom;Italy;China
2EUCTR2020-000384-23-ES
(EUCTR)
17/05/202228/03/2022A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis (FSGS).A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis - PoCP study in FSGS Glomerulosclerosis
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Product Code: BI 764198
INN or Proposed INN: None yet
Other descriptive name: BI 764198
Boehringer Ingelheim España S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2United States;Hungary;Belgium;France;Spain;Ireland;Australia;Germany;United Kingdom;Italy
3NCT05213624
(ClinicalTrials.gov)
March 10, 202227/1/2022A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental GlomerulosclerosisA Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental GlomerulosclerosisKidney Disease, ChronicDrug: BI 764198;Drug: PlaceboBoehringer IngelheimNULLRecruiting18 Years75 YearsAll60Phase 2United States;Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom